{"preliminary_commentary":{"by_channel":{"x_thread":136,"youtube":9,"podcast":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05499390\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T02:52:13.793Z","note":"Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.","passages_read":null,"text":"The commentary discusses ivonescimab versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, including the PD-1/VEGF approach and subgroup interpretation. Speakers raise whether pembrolizumab monotherapy is an appropriate comparator for PD-L1-low disease, whether overall survival should be a primary endpoint, and whether findings from the China-only study translate beyond that setting. Discussion also covers control-arm limitations, censoring, toxicity, predictive biomarkers, and whether the data should change practice pending global-trial evidence."},"name":"HARMONi-2","nct_id":"NCT05499390","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=harmoni-2-nct05499390. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects receive AK112 monotherapy intravenously (IV), selected dose.","label":"AK112","type":"EXPERIMENTAL"},{"description":"Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.","label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Advanced Non-small-cell Lung Cancer"],"enrollment":{"count":398,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AK112","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-09","lead_sponsor":"Akeso","official_title":"A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-01-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS assessed by IRRC per RECIST v1.1","timeFrame":"Up to 2 approximately years"}],"references":[{"citation":"Wang L, Yao W, Shen H, Xie C, Chen H, Chen K, Su W, Gan X, Zhuo M, Chen E, Xu Z, Zhang Y, Wang M, Ma R, Wu H, Zhang Z, Ye F, Moore AC, Zhou C. Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study. Future Oncol. 2026 Jan;22(1):27-36. doi: 10.1080/14796694.2025.2601138. Epub 2025 Dec 28.","pmid":"41457351","type":"DERIVED"},{"citation":"Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, Zhong H, Li J, Cheng Y, Sun Y, Ge H, Yao J, Shi Q, Zhou M, Chen B, Han Z, Wang J, Bu Q, Zhao Y, Chen J, Nie L, Li G, Li X, Yu X, Ji Y, Sun D, Ai X, Chu Q, Lin Y, Hao J, Huang D, Zhou C, Shan J, Yang H, Liu X, Wang J, Shang Y, Mei X, Yang J, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhou C. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 2025 Mar 8;405(10481):839-849. doi: 10.1016/S0140-6736(24)02722-3.","pmid":"40057343","type":"DERIVED"}],"start_date":{"date":"2022-11-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"AK112 in Advanced Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05499390"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/harmoni-2-nct05499390"}